micro-community-banner
 
  • Saved

3yr
Non-aura visual disturbance with high visual aura rating scale scores has stronger association with migraine chronification than typical aura - PubMed

Non-aura visual disturbance with high visual aura rating scale scores has stronger association with migraine chronification than typical aura - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36068697/

1 Keelung Hospital of the Ministry of Health and Welfare, Keelung, Taiwan. 2 Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. 3 School...


Conclusion: Presence of non-aura transient visual disturbance may suggest a higher migraine-related disability and is linked to higher risk of chronic migraine than typical migraine aura in migraine patients. Further studies are needed to elucidate the potential mechanism.

  • Saved

3yr
Preventive migraine treatment in mitochondrial diseases: a case report of erenumab efficacy and literature review - PubMed

Preventive migraine treatment in mitochondrial diseases: a case report of erenumab efficacy and literature review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36097203/

Migraine is a common condition in mitochondrial diseases, with a higher prevalence than in the general population. Although several clinical studies support the hypothesis that mitochondrial dysfunction plays a central...


Conclusion/Relevance: Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) or against its receptor are innovative and specific therapies for migraine prophylaxis. This class of drugs is particularly suitable for subjects, such as those suffering from genetically determined mitochondrial dysfunction, in which pharmacological...

  • Saved

3yr
Preventive treatment can reverse cognitive impairment in chronic migraine - The Journal of Headache and Pain

Preventive treatment can reverse cognitive impairment in chronic migraine - The Journal of Headache and Pain

Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01486-w

Objective To study the impact of chronic migraine (CM) on the cognition and quality of life (QoL) of patients in the interictal period, and to analyse the degree of reversibility...


Conclusions: This study confirms poor cognitive performance that is not explained by migraine pain itself, as it occurs in the interictal period, irrespective of the patient’s emotional status. Our findings show that these effects are reversible in some cases with preventive treatment of CM, reaffirming the important impact of this condition...

  • Saved

3yr
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial - The Journal of Headache and Pain

Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial - The Journal of Headache and Pain

Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01480-2

Background In Italy, monoclonal antibodies targeting the CGRP pathway are subsidized for the preventive treatment of high frequency and chronic migraine (CM) in patients with a MIgraine Disability ASsessment (MIDAS)...


Conclusion: MIDASRes only partly reflects the 12-month outcome of erenumab treatment in CM, as it excludes more than one third of responders. A criterion based on the alternative consideration of ≥ 50% reduction in MIDAS score or MMDs in the first three months of treatment represents a more precise and inclusive option.

  • Saved

3yr
Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study

Safety and efficacy of erenumab in patients with trigeminal neuralgia in Denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study

Source : https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00294-0/fulltext

Trigeminal neuralgia is a severe facial pain disorder that is difficult to treat. Erenumab, a monoclonal antibody against the calcitonin gene-related peptide (CGRP) receptor, has proven efficacy in migraine. Erenumab...


Interpretation: Erenumab did not reduce pain intensity compared with placebo in patients with trigeminal neuralgia and CGRP probably does not have an important role in paroxysmal pain. Well tolerated, effective treatments in trigeminal neuralgia are still needed.